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Introduction
Interleukin-36-receptor antagonist deficiency (DITRA) is
a recently described auto-inflammatory disease1, charac-
terized by repeated flares of generalized pustular psoria-
sis, high fever, asthenia and systemic inflammation. This
condition is caused by homozygous missense mutation
in the IL36RN gene, encoding the interleukin-36-receptor
antagonist (IL-36Ra), an anti-inflammatory cytokine. We
report herein the first exhaustive clinical description of
an infant with DITRA, who was successfully treated with
anakinra.
Case report
Y.M. is the first son of Tunisian consanguineous parents
who developed, at two weeks of life, an erythematous
and scaly eruption, with subsequent rapid evolution
toward generalized pustular psoriasis. Afterwards, cuta-
neous flares of diffuse erythematous rash and pustules
involving the whole body appeared, with a once weekly
periodicity. Intense irritability was present during flares
without fever. Moreover, since 1 month of age the infant
presented diarrhea, dysphagia and reduced feeding rate,
with failure to thrive. Laboratory tests during acute
flares showed marked leukocytosis, thrombocytosis and
anemia without C-reactive protein elevation. Skin biopsy
and clinical presentation were consistent with pustular
psoriasis, nevertheless, the patient did not respond to
high-potency topical corticosteroids and retinoid acid.
As the patient presented repeated skin flares early after
birth, as well as serious constitutional distress with failure
to thrive, an auto-inflammatory syndrome like DIRA
(interleukine-1 receptor antagonist deficiency)[2] or
DITRA was considered. The hypothesis was reinforced
by parental consanguinity, and absence of skin lesions
improvement under standard topical treatment. Genetic
analyses showed a homozygous mutation in the IL36RN
gene (L27P) which represents the same mutation recently
described in DITRA patients[1,3]. At 6 months we
started treatment with the recombinant IL-1 receptor
antagonist anakinra with efficacy both on constitutional
symptoms and skin involvement.
Discussion
To the best of our knowledge, we report the first
detailed clinical description of an infant with DITRA.
Even if neonatal onset has been already reported[1], no
detailed clinical description was provided, probably due
to late diagnosis. Our clinical report brings new clinical
characteristics and educational iconography.We even
report, for the first time, a favorable clinical response of
this disease to anakinra treatment.
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